title: Toxic peripheral neuropathy with demyelination in Sprague-Dawley rats given CGS 21595--a 5-lipoxygenase inhibitor.
abstract: Male and female Sprague-Dawley rats were given CGS 21595, a pro-drug that is almost immediately metabolized to CGS 19213, a naphthoquinone that acts as a 5-lipoxygenase inhibitor. The compound was administered by gavage to five groups of Sprague-Dawley rats (group Nos. 1, 5, n = 30; group Nos. 2-4, n = 20) at daily doses of 0, 50, 150, 500, or 1,000 mg/kg for 13 weeks. Rats in the higher dose groups had a reduced weight gain, but significant neurologic signs were not observed. A peripheral neuropathy consisting predominantly of myelin destruction in the spinal nerve roots and sciatic nerves in male rats treated with greater than or equal to 150 mg/kg CGS 21595 and in female rats treated with greater than or equal to 50 mg/kg CGS 21595 for 13 weeks. This lesion was not fully reversible after a recovery period of 4 weeks. Lesions consisted of ballooning of myelin sheaths, infiltration by macrophages, demyelination, and occasional areas of remyelination. Axons were generally preserved, and the brain and spinal cord were not affected. Male and female rats in all treatment groups had cytoplasmic hyaline droplets in the proximal renal tubules. This change was reversible after 4 weeks and was not associated with any other adverse effects on the kidney.
authors.affiliation: Subdivision of Pathology, CIBA-GEIGY Corporation, Summit, NJ.
authors.forename: D E
authors.initials: DE
authors.lastname: Gunson
authors.forename: P S
authors.initials: PS
authors.lastname: Sahota
authors.forename: W O
authors.initials: WO
authors.lastname: Iverson
authors.forename: R Y
authors.initials: RY
authors.lastname: Chau
authors.forename: G M
authors.initials: GM
authors.lastname: McCormick
authors.forename: V M
authors.initials: VM
authors.lastname: Traina
mesh_terms: D015057:1-Naphthylamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000633:toxicity; D000284:Administration, Oral; D000818:Animals; D004305:Dose-Response Relationship, Drug; D005260:Female; D007687:Kidney Tubules, Proximal / Q000187:drug effects; D016859:Lipoxygenase Inhibitors / Q000008:administration & dosage / Q000737:chemistry / Q000633:toxicity*; D008297:Male; D015394:Molecular Structure; D009186:Myelin Sheath / Q000187:drug effects; D011355:Prodrugs / Q000008:administration & dosage / Q000737:chemistry / Q000633:toxicity*; D051381:Rats; D011919:Rats, Inbred Strains; D012584:Sciatic Nerve / Q000187:drug effects*; D013126:Spinal Nerve Roots / Q000187:drug effects*; D015430:Weight Gain / Q000187:drug effects
chemical_list: D016859:Lipoxygenase Inhibitors; D011355:Prodrugs; C075704:CGS 21595; D015057:1-Naphthylamine